The treatment, called ivonescimab, has become a symbol of China’s rise in drug development.
This post first appeared in The New York Times – Business. Read the original article.F.D.A. Rejects Closely Watched Lung Cancer Drug From China
The New York Times – Business:
Written by
in

Leave a Reply